Related Experiment Videos
[DTIC in malignant melanoma: a perspective (author's transl)]
Abstract:
Effective therapy of malignant melanoma is still problematic. A variety of chemotherapeutic agents has proved to be ineffective in this tumour. The most extensively used chemotherapeutic agent for treatment of melanoma is DTIC (dimethyl-triaceno-imidazol-carboxamide). The objective response rate in monotherapy schedules has been reported to be up to 25%. Combination therapy with other cytostatic agents did not improve the results of DTIC alone. Experimental studies and clinical investigations have demonstrated that chemotherapy can be combined successfully with immunotherapy by potentiating the effect of tumour elimination. A review of the clinical studies with DTIC in malignant melanoma is presented.
Insights
Chemotherapy for malignant melanoma, like DTIC (dimethyl-triaceno-imidazol-carboxamide), has limited efficacy. Combining chemotherapy with immunotherapy shows promise for enhancing tumor elimination in melanoma treatment.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Context:
- Malignant melanoma presents therapeutic challenges.
- Current chemotherapeutic agents, including DTIC (dimethyl-triaceno-imidazol-carboxamide), show limited objective response rates (up to 25%) in melanoma monotherapy.
- Combination with other cytostatic agents has not improved DTIC efficacy.
Purpose:
- To review clinical studies on DTIC in malignant melanoma.
- To explore the potential of combining chemotherapy with immunotherapy for melanoma treatment.
Summary:
- DTIC is a primary chemotherapeutic agent for melanoma, but its monotherapy effectiveness is restricted.
- Combining DTIC chemotherapy with immunotherapy may enhance tumor elimination.
- This review focuses on clinical data regarding DTIC in malignant melanoma.
Impact:
- Highlights the limitations of current melanoma chemotherapy.
- Suggests a promising therapeutic strategy by combining chemotherapy with immunotherapy.
- Provides a review of clinical evidence for DTIC in malignant melanoma treatment.